Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.The company has 3 R&D and 5 manufacturing facilities.
What Alembic files
- Others153
- Updates64
- Investor Meet40
- Important39
- Dividend/Bonus19
- Board Meeting15
Alembic Pharma announced its 16th Annual General Meeting on August 5, 2026, to be held virtually. The final dividend record date is July 29, 2026, with payments starting August 6, 2026. The FY2025-26 Annual Report is now accessible.
Alembic Pharmaceuticals Limited has informed the Exchange about Agreements
Alembic Pharma's API-III Facility at Karakhadi successfully cleared inspection by Brazil's health authority, without any observations. This strengthens its operational standing and access for multiple APIs in the Brazilian market.
Alembic Pharma's Karakhadi Injectable facility has received a crucial inspection report from the US drug regulator after its recent review. This marks a significant step for the plant's operational standing.
Alembic Pharma converted its UAE branch office into a Wholly Owned Subsidiary, Alembic Pharmaceuticals Scientific Office L.L.C. This move consolidates its international presence. The cost of acquisition was AED 50,000 for 100% control.